Comorbidity burden in adult atopic dermatitis: A population‐based study

Author:

Thyssen Jacob P.1ORCID,Henrohn Dan23ORCID,Neary Maureen P.4ORCID,Geale Kirk56ORCID,Dun Alexander R.5ORCID,Ortsäter Gustaf5ORCID,Lindberg Ingrid5ORCID,De Geer Anna2ORCID,Neregård Petra2ORCID,Cha Amy7ORCID,Cappelleri Joseph C.8ORCID,Romero William9ORCID,von Kobyletzki Laura10ORCID

Affiliation:

1. Department of Dermatology and Venereology, Bispebjerg Hospital University of Copenhagen Copenhagen Denmark

2. Department of Inflammation and Immunology Pfizer AB Stockholm Sweden

3. Department of Medical Sciences Uppsala University Uppsala Sweden

4. Department of Inflammation and Immunology Pfizer Inc. Collegeville Pennsylvania USA

5. Quantify Research AB Stockholm Sweden

6. Dermatology and Venereology, Department of Public Health and Clinical Medicine Umeå University Umeå Sweden

7. Department of Inflammation and Immunology Pfizer Inc. New York New York USA

8. Global Biometrics and Data Management (Statistics) Pfizer Inc. Groton Connecticut USA

9. Department of Inflammation and Immunology Pfizer Ltd. Surrey UK

10. Department of Occupational and Environmental Dermatology, Skåne University Hospital Lund University Lund Sweden

Abstract

AbstractBackgroundAtopic dermatitis (AD) is a chronic inflammatory skin disease that has been shown to be associated with allergic comorbidities. However, studies examining comorbidities in patients with AD are incomplete, which may contribute to suboptimal care.ObjectivesThe objective was to compare the risk of developing different allergic and nonallergic comorbidities among adult patients with AD to that of a matched reference cohort in Sweden.MethodsThis was a nationwide population‐based cohort study using longitudinal data from primary and specialist care registers. AD patients were identified by confirmed diagnosis in primary or specialist care. A non‐AD reference cohort was randomly drawn from the general population and matched 1:1 with the AD patients on age, gender, and geographical region. The risk of developing the following conditions was evaluated: asthma, food hypersensitivity, allergic rhinitis, neurological disorders, psychiatric disorders, infections, immunological & inflammatory disorders, type 1 diabetes (T1D), type 2 diabetes (T2D), endocrine & metabolic disorders, skeletal disorders, ocular disorders, cardiovascular diseases, and malignancies.ResultsThis study included 107,774 AD patients [mild‐to‐moderate (n = 92,413) and severe (n = 15,361)] and an equally‐sized reference cohort. AD patients displayed a higher risk of developing comorbid conditions for all investigated categories, except for T1D, compared with the reference cohort. The highest risk compared with the reference cohort was observed for allergic comorbidities followed by immunological & inflammatory disorders (hazard ratio: 2.15) and infections (hazard ratio: 2.01). Patients with AD also had higher risk of developing multiple comorbidities (2 or more). The risk of comorbidity onset increased alongside AD severity and patients with active AD were associated with increased risk of comorbidity onset compared with patients in remission.ConclusionsAD patients are at an increased risk of developing many comorbidities that extend beyond allergic conditions. This study highlights the need for interdisciplinary follow‐up of comorbidities in the management of AD patients to reduce overall patient burden.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3